A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo- Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause.

Trial Profile

A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo- Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2014

At a glance

  • Drugs Paroxetine (Primary)
  • Indications Hot flashes; Menopausal syndrome; Vasomotor symptoms
  • Focus Registrational; Therapeutic Use
  • Sponsors Noven Pharmaceuticals
  • Most Recent Events

    • 14 Oct 2014 A pooled analysis of the effects of paroxetine on body weight and sexual function has been published in Menopause, according to a Noven Pharmaceuticals media release.
    • 14 Oct 2014 Pooled analysis of the effects of paroxetine on body weight and sexual function reported in a Noven Pharmaceuticals media release.
    • 12 Oct 2013 Pooled analysis for the effect of paroxetine on body weight and sexual function presented at the 24th Annual Meeting of the North American Menopause Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top